RecruitingPHASE1, PHASE2NCT06316856

CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies

Studying Acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Beijing GoBroad Hospital
Intervention
Autologous CD5 CAR T-cells(drug)
Enrollment
54 enrolled
Eligibility
1-70 years · All sexes
Timeline
20242026

Study locations (4)

Collaborators

The General Hospital of Western Theater Command · Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai · Shanghai Liquan Hospital · Central People's Hospital of Zhanjiang · First Affiliated Hospital of Guangxi Medical University

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06316856 on ClinicalTrials.gov

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute lymphoblastic leukemia

← Back to all trials